Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 2
1998 2
2000 1
2001 3
2002 1
2003 2
2004 5
2005 4
2006 1
2007 3
2008 1
2009 3
2010 2
2011 2
2012 1
2016 1
2018 6
2019 5
2020 7
2021 12
2022 12
2023 6
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

80 results

Results by year

Filters applied: . Clear all
Page 1
Intestinal Permeation Enhancers for Oral Delivery of Macromolecules: A Comparison between Salcaprozate Sodium (SNAC) and Sodium Caprate (C(10)).
Twarog C, Fattah S, Heade J, Maher S, Fattal E, Brayden DJ. Twarog C, et al. Pharmaceutics. 2019 Feb 13;11(2):78. doi: 10.3390/pharmaceutics11020078. Pharmaceutics. 2019. PMID: 30781867 Free PMC article. Review.
Salcaprozate sodium (SNAC) and sodium caprate (C(10)) are two of the most advanced intestinal permeation enhancers (PEs) that have been tested in clinical trials for oral delivery of macromolecules. ...
Salcaprozate sodium (SNAC) and sodium caprate (C(10)) are two of the most advanced intestinal permeation enhancers (PEs) that …
Salcaprozate sodium (SNAC) enhances permeability of octreotide across isolated rat and human intestinal epithelial mucosae in Ussing chambers.
Fattah S, Ismaiel M, Murphy B, Rulikowska A, Frias JM, Winter DC, Brayden DJ. Fattah S, et al. Eur J Pharm Sci. 2020 Nov 1;154:105509. doi: 10.1016/j.ejps.2020.105509. Epub 2020 Aug 8. Eur J Pharm Sci. 2020. PMID: 32777258 Free article.
Oral delivery of the octapeptide is a challenge due mainly to low intestinal epithelial permeability. The intestinal permeation enhancer (PE) salcaprozate sodium (SNAC) has Generally Regarded As Safe (GRAS) status and is a component of an approved oral peptide formu …
Oral delivery of the octapeptide is a challenge due mainly to low intestinal epithelial permeability. The intestinal permeation enhancer (PE …
A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes.
Andersen A, Knop FK, Vilsbøll T. Andersen A, et al. Drugs. 2021 Jun;81(9):1003-1030. doi: 10.1007/s40265-021-01499-w. Epub 2021 May 8. Drugs. 2021. PMID: 33964002 Free PMC article. Review.
It is the first GLP-1RA developed for oral administration, and it comprises a co-formulation of the peptide semaglutide with the absorption enhancer sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, which overcomes the challenges of peptid …
It is the first GLP-1RA developed for oral administration, and it comprises a co-formulation of the peptide semaglutide with the absorption …
A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes.
Aroda VR, Blonde L, Pratley RE. Aroda VR, et al. Rev Endocr Metab Disord. 2022 Oct;23(5):979-994. doi: 10.1007/s11154-022-09735-8. Epub 2022 Jul 15. Rev Endocr Metab Disord. 2022. PMID: 35838946 Free PMC article. Review.
An oral formulation of semaglutide was therefore developed by co-formulating semaglutide with sodium N-(8-[2-hydroxybenzoyl]amino)caprylate, a well-characterized transcellular permeation enhancer, to produce the first orally administered …
An oral formulation of semaglutide was therefore developed by co-formulating semaglutide with sodium N-(8-[2-hydroxy …
Characterization of the physicochemical interactions between exenatide and two intestinal permeation enhancers: Sodium caprate (C(10)) and salcaprozate sodium (SNAC).
Twarog C, Fattal E, Noiray M, Illel B, Brayden DJ, Taverna M, Hillaireau H. Twarog C, et al. Int J Pharm. 2022 Oct 15;626:122131. doi: 10.1016/j.ijpharm.2022.122131. Epub 2022 Aug 24. Int J Pharm. 2022. PMID: 36028084
Increased oral bioavailability for oral peptide candidates has been reported from clinical trials when either salcaprozate sodium (SNAC) or sodium caprate (C(10)) is incorporated in the formulation. ...
Increased oral bioavailability for oral peptide candidates has been reported from clinical trials when either salcaprozate sodium …
Oral Semaglutide: A Review of the First Oral Glucagon-Like Peptide 1 Receptor Agonist.
Bucheit JD, Pamulapati LG, Carter N, Malloy K, Dixon DL, Sisson EM. Bucheit JD, et al. Diabetes Technol Ther. 2020 Jan;22(1):10-18. doi: 10.1089/dia.2019.0185. Epub 2019 Oct 1. Diabetes Technol Ther. 2020. PMID: 31436480 Review.
However, subcutaneous administration of these agents remains a major reason for their underutilization. A new coformulation of semaglutide with sodium N-[8-(2-hydroxybenzoyl) amino caprylate (SNAC) is the first oral GLP-1 RA reviewed by t …
However, subcutaneous administration of these agents remains a major reason for their underutilization. A new coformulation of semaglutide w …
Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects with Renal Impairment.
Granhall C, Søndergaard FL, Thomsen M, Anderson TW. Granhall C, et al. Clin Pharmacokinet. 2018 Dec;57(12):1571-1580. doi: 10.1007/s40262-018-0649-2. Clin Pharmacokinet. 2018. PMID: 29623579 Free PMC article. Clinical Trial.
BACKGROUND: Semaglutide, a glucagon-like peptide-1 (GLP-1) analogue, has been co-formulated with the absorption enhancer sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC) as a tablet for oral administration. ...
BACKGROUND: Semaglutide, a glucagon-like peptide-1 (GLP-1) analogue, has been co-formulated with the absorption enhancer sodium N-( …
The combined effect of permeation enhancement and proteolysis inhibition on the systemic exposure of orally administrated peptides: Salcaprozate sodium, soybean trypsin inhibitor, and teriparatide study in pigs.
Burshtein G, Itin C, Tang JCY, Galitzer H, Fraser WD, Schwartz P. Burshtein G, et al. Int J Pharm X. 2021 Oct 8;3:100097. doi: 10.1016/j.ijpx.2021.100097. eCollection 2021 Dec. Int J Pharm X. 2021. PMID: 34704013 Free PMC article.
In the discussed study conducted in pigs, an investigation was undertaken to assess the effect of combination of a permeation enhancer - salcaprozate sodium, and a proteolysis inhibitor - soybean trypsin inhibitor, on the systemic exposure of the peptide teriparatid …
In the discussed study conducted in pigs, an investigation was undertaken to assess the effect of combination of a permeation enhancer - …
Synthesis of salcaprozate sodium and its significance in enhancing pancreatic kininogenase absorption performance.
Lv Z, Luo QD, Tang ZY, Lv XH, Wu T, Huang LK, Tang C. Lv Z, et al. Pharmacol Res Perspect. 2024 Apr;12(2):e1186. doi: 10.1002/prp2.1186. Pharmacol Res Perspect. 2024. PMID: 38511246 Free PMC article.
We conducted pharmacokinetic research wherein salcaprozate sodium (SNAC) was utilized as a penetration enhancer by incorporating it into pancreatic kininogenase (PK) to improve the bioavailability of pancreatic kininogenase enteric-coated tablets. ...
We conducted pharmacokinetic research wherein salcaprozate sodium (SNAC) was utilized as a penetration enhancer by incorporati …
80 results